Arbennek Healthcare Limited 13863674 false 2023-04-01 2024-03-30 2024-03-30 The principal activity of the company is 86210 - General medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true true 13863674 2023-04-01 2024-03-30 13863674 2024-03-30 13863674 core:ShareCapital 2024-03-30 13863674 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-30 13863674 bus:SmallEntities 2023-04-01 2024-03-30 13863674 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-30 13863674 bus:FullAccounts 2023-04-01 2024-03-30 13863674 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-30 13863674 bus:RegisteredOffice 2023-04-01 2024-03-30 13863674 bus:Director3 2023-04-01 2024-03-30 13863674 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-30 13863674 1 2023-04-01 2024-03-30 13863674 countries:EnglandWales 2023-04-01 2024-03-30 13863674 2022-01-21 2023-03-31 13863674 2023-03-31 13863674 core:ShareCapital 2023-03-31 13863674 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 iso4217:GBP xbrli:pure

Registration number: 13863674

Arbennek Healthcare Limited

Annual Report and Unaudited Filleted Abridged Financial Statements

for the Period from 1 April 2023 to 30 March 2024

 

Arbennek Healthcare Limited

Contents

Abridged Balance Sheet

1

Notes to the Unaudited Abridged Financial Statements

2

 

Arbennek Healthcare Limited

(Registration number: 13863674)
Abridged Balance Sheet as at 30 March 2024

Note

2024
£

2023
£

Current assets

 

Debtors

-

117,327

Cash at bank and in hand

 

283,307

90,898

 

283,307

208,225

Creditors: Amounts falling due within one year

(282,907)

(207,825)

Net assets

 

400

400

Capital and reserves

 

Called up share capital

400

400

Total equity

 

400

400

For the financial period ending 30 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the Board on 13 March 2025 and signed on its behalf by:
 

Dr R Murthy

Director

 

Arbennek Healthcare Limited

Notes to the Unaudited Abridged Financial Statements for the Period from 1 April 2023 to 30 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
The Clays Practice
Victoria Road
Roche
Cornwall
PL26 8JF
Somerset

These financial statements were authorised for issue by the Board on 13 March 2025.

2

Accounting policies

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

The accounting period is less than 12 months due to it being the first post incorporation period, subsequent periods will be 12 months in length.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 37 (2023 - 12).